Abstract
Adalimumab serum concentration to choose a subsequent biological DMARD in patients with rheumatoid arthritis (ADDORA-switch): results of a blinded randomised test-treatment trial.
Published Version
Join us for a 30 min session where you can share your feedback and ask us any queries you have